Seeking Alpha

Deep.Blue

Deep.Blue
Send Message
View as an RSS Feed
View Deep.Blue's Comments BY TICKER:
Latest  |  Highest rated
  • Expecting Positive Phase III Results For GTx's Cancer Muscle-Wasting Drug [View article]
    my guess is third week of august
    Jul 26 02:52 PM | Likes Like |Link to Comment
  • Expecting Positive Phase III Results For GTx's Cancer Muscle-Wasting Drug [View article]
    Feuerstein may get investigated this time.
    Jul 26 12:38 PM | 4 Likes Like |Link to Comment
  • Vascepa Scripts Barrel Forward To Q2 Earnings [View article]
    just cant average one week with 5 work days and another week with four work days, unless we are going to a 4.5 day workweek...
    Jul 23 03:19 PM | Likes Like |Link to Comment
  • Vascepa Scripts Barrel Forward To Q2 Earnings [View article]
    why would you average anything? scripts are a function of doc office visits and penetration of the drug on a realtime basis with a week lag in reporting. if you average the two weeks, then you are assuming that there is a holiday every ten working days on an ongoing basis.

    foolish.
    Jul 22 10:59 AM | 1 Like Like |Link to Comment
  • Is Nymox The Next Unknown Biotech Turned High Flyer? [View article]
    why dont you tell us bobby as you seem to know the answers to your own questions.
    Jul 16 07:06 PM | Likes Like |Link to Comment
  • Amarin's NCE Update [View instapost]
    if correct, also lends credence to the theory that FDA is inclined to approve Anchor this year and before outcomes data. if they were to push Anchor until post Reduce IT, then they would be inclined to go ahead w their exclusivity determination now.
    Jul 16 12:03 PM | Likes Like |Link to Comment
  • Is Nymox The Next Unknown Biotech Turned High Flyer? [View article]
    Thanks Andrew. Lets also not forget the P2 of 1207 for early stage prostate cancer. If this materializes, the opportunity could be bigger than for BPH.

    Wall Street assigns high valuations for prostate cancer drugs.
    Jul 15 05:46 PM | Likes Like |Link to Comment
  • A 1-2 Punch At Amarin Longs [View article]
    Last week scripts were down by 7.7 pct at 4043. This was July 4th week.

    Under the realistic to conservative assumption that docs didn't have office hours on July fourth (and worked on July 5th), then 4043 was for a four day week, or 1011 per day. Convert that daily into a weekly and you get 5054 normalized for the holiday. 5054 would be 25 pct growth for the week. If docs worked less that four days, then the growth would be even bigger...

    Tier 2 kicking in big now.
    Jul 15 10:05 AM | Likes Like |Link to Comment
  • Analysis Of Amarin's Offering And Vascepa Update [View article]
    Kid, just do your cash flow analysis and quit stating the obvious.
    Jul 8 10:42 PM | 1 Like Like |Link to Comment
  • Vascepa Scripts: Cyclical Growth Or Slowdown? [View article]
    kid, you are a master of the obvious.
    Jul 8 11:19 AM | 1 Like Like |Link to Comment
  • GTX Incorporated: Its 'Other' Drug, Capesaris [View article]
    Thanks for writing about Capesaris. If P2 data comes back clean on safety, we could see this drug get valued up from almost zero today. Also, you might want to also take into consideration MDVNs Xtandi into your larger analysis of approved drugs for post chemo and pre chemo prostate cancer.
    Jul 5 05:18 PM | 1 Like Like |Link to Comment
  • Cover Your Amarin Short And Go Long [View article]
    kid - you never did your cash flow analysis to back up your article on cash burn. i did it for you. the internet lets anyone write anything these days. amateur hour non stop, everywhere.
    Jul 3 12:13 PM | 5 Likes Like |Link to Comment
  • Amarin's AdCom: Two Fish With One Hook [View instapost]
    of course they could change their mind, and if they do so they send big reverberations all through the drug development world. the fact is they want the Reduce IT data. getting that data is jeopardized by reneging on Anchor. FDA wants their own JELIS.
    Jul 1 05:28 PM | 1 Like Like |Link to Comment
  • Amarin's AdCom: Two Fish With One Hook [View instapost]
    If FDA had changed their mind and was going to renege on the SPA, then they would have had to notify AMRN in writing and in turn AMRN would have to disclose this info.

    Given that - 1) FDA accepted the Anchor sNDA early and 2) we have heard nothing else - seems to clearly clearly point to the fact that FDA is standing behind the SPA.
    Jul 1 04:19 PM | 3 Likes Like |Link to Comment
  • Amarin's AdCom: Two Fish With One Hook [View instapost]
    defend yourself feuerstein. c'mon. can you actually use facts to back up your off the cuff statements? can you do this feuerstein or will you just hide and wait to make up something else?
    Jul 1 02:26 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
131 Comments
201 Likes